Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine in metastatic pancreatic cancer
NCT01598584Phase 3Withdrawn
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mirtazapine in major depressive disorder (MDD), anxiety disorder, sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jun 2012; status: withdrawn.
02
Drugs
mirtazapine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT01598584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01598584.